معرفی
Clinical Associate Professor Eric Hau is a prominent researcher and clinician at the Westmead Clinical School, part of the Sydney Medical School at the University of Sydney. His work focuses on advancing cancer treatment through innovative radiation therapy approaches and clinical research, particularly in lung cancer and brain tumors. His clinical specialty is oncology, with significant contributions to understanding radiation therapy applications across various cancer types.
- University: University of Sydney
- School: Sydney Medical School
- Department: Westmead Clinical School
- Academic Rank: Clinical Associate Professor
- Clinical Specialty: Oncology
Professor Hau's research spans multiple critical areas in oncology, with particular emphasis on lung cancer treatment optimization, brain tumor radiosensitization, and the integration of immunotherapy with radiation therapy. His work addresses fundamental challenges in cancer treatment including tumor hypoxia, metabolic pathways, and radiation resistance mechanisms. He has made significant contributions to understanding cardiac complications from thoracic radiation and has pioneered approaches to personalize radiation therapy through phenotypic medicine. His research portfolio demonstrates a consistent focus on translating basic science discoveries into clinical applications that improve patient outcomes.
Analysis of Professor Hau's recent publications reveals a strong focus on lung cancer treatment optimization, particularly in non-small cell and small cell lung cancer. His work frequently examines the intersection of radiation therapy with immunotherapy, addressing critical questions about treatment sequencing, efficacy, and toxicity. A significant portion of his research investigates brain metastases management and strategies to overcome radiation resistance through metabolic targeting. His publications demonstrate methodological diversity, including systematic reviews, clinical trials, registry studies, and mechanistic investigations, reflecting his comprehensive approach to advancing cancer treatment.
Professor Hau has secured competitive research funding for significant projects including a 2022 Cancer Institute NSW Equipment Grant for advanced microscopy to support translational cancer research, a 2020 NHMRC Ideas Grant investigating molecular mechanisms of cell death in radiotherapy, and a 2019 Mark Hughes Foundation Project Grant targeting hypoxia in diffuse intrinsic pontine gliomas. These grants highlight his leadership in developing innovative approaches to radiosensitization and his commitment to advancing translational cancer research at the Westmead Health Precinct.
Professor Hau is actively involved in multi-institutional collaborative research through the Australian Computer-Assisted Theragnostics (AusCAT) network and participates in major clinical trials including the CHEST-RT (TROG 20.01) trial. His work connects basic science investigations with clinical applications, particularly in developing strategies to overcome radiation resistance through metabolic targeting and hypoxia modulation. His leadership extends to implementing complex radiotherapy techniques safely across Australian institutions, as demonstrated in his collaborative work on stereotactic ablative body radiotherapy implementation.
